Ginkgo Bioworks Holdings Inc.
09/04/2024 | Press release | Distributed by Public on 09/04/2024 16:49
Material Event Form 8 K
Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or StandardÍž Transfer of Listing.
On September 3, 2024, the New York Stock Exchange (the "NYSE") notified Ginkgo Bioworks Holdings, Inc. (the "Company"), and, on September 4, 2024, publicly announced, that the NYSE has determined to (a) commence proceedings to delist the Company's public warrants which were previously issued in connection with Soaring Eagle Acquisition Corp.'s initial public offering (the "Warrants"), each Warrant exercisable for one-fortieth (1/40) of one share of the Company's Class A common stock, par value $0.0001 per share (the "Class A Common Stock"), at an exercise price of $11.50 per Warrant, and listed to trade on the NYSE under the symbol "DNA.WS" and (b) immediately suspend trading in the Warrants due to "abnormally low" trading price levels pursuant to Section 802.01D of the NYSE Listed Company Manual.
Trading in the Company's Class A Common Stock will be unaffected and will continue on the NYSE under the symbol "DNA".